Behind the showdown between President Barack Obama and Congress over the Iran nuclear deal is a second dispute that could cost the White House allies it needs to ensure the agreement survives: Whether and when to renew a key law…
The Senate HELP Committee held its third markup of legislation that will improve the development process and increase investment in drugs that address health needs.
The REGROW Act—which aligns with recommendations included in a recent BPC report—modernizes FDA’s current regulatory approach toward safe and effective cell therapies.
The Senate HELP Committee’s health innovation legislative package includes three bills that align with BPC’s recommendations.
To keep the United States at the forefront of medical innovation, federal policies need to incentivize new technologies for the benefits of patients.
With the JPOA deadline for the negotiations between the P5+1 and Iran rapidly approaching, what questions remain unanswered and what next steps should Congress be considering in response to any scenario?
As the P5+1 approaches the July 20th deadline for a final Iran nuclear deal, what standards should Congress seek in an acceptable agreement? And what are the stakes for the United States and its allies? BPC, the Foreign Policy Initiative, and the Foundation for Defense of Democracies hosted a public forum on these and other questions featuring Members of Congress and experts.
Last weekend, while much of the foreign policy community was focused on the turmoil in Ukraine, congressional leaders reached out to the White House on another issue of international significance: preventing a nuclear Iran. In a rare bipartisan and bicameral…